Concord Medical Services (NYSE:CCM) Raised to Hold at Wall Street Zen

Concord Medical Services (NYSE:CCM) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a report issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Concord Medical Services in a research note on Tuesday, May 26th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Concord Medical Services currently has an average rating of “Sell”.

Concord Medical Services Stock Performance

Shares of NYSE:CCM opened at $4.72 on Friday. The business’s 50 day moving average is $4.62 and its 200 day moving average is $4.28. Concord Medical Services has a 12-month low of $3.18 and a 12-month high of $6.98. The company has a quick ratio of 0.46, a current ratio of 0.48 and a debt-to-equity ratio of 1.33.

Concord Medical Services Company Profile

Concord Medical Services Holdings Limited is one of China’s leading providers of radiotherapy equipment and oncology services. The company specializes in supplying and operating advanced radiotherapy machines, including linear accelerators, computed tomography (CT) simulators and brachytherapy units, to public and private hospitals. Through its integrated service model, Concord Medical Services delivers treatment planning, machine maintenance and clinical support to enhance the precision and effectiveness of cancer therapies.

Founded in 1997 and headquartered in Beijing, Concord Medical Services has developed an extensive network of oncology centers across major cities and provinces in China.